Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia, At The IASP 2024 World Congress On Pain
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented positive Phase 3 trial data for TNX-102 SL, showing significant improvements in fibromyalgia pain and sleep quality. The FDA has granted Fast Track designation, with an NDA submission expected in the second half of 2024.
August 12, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-102 SL demonstrated significant Phase 3 trial results for fibromyalgia, improving pain and sleep quality. The FDA has granted Fast Track designation, with an NDA submission expected in the second half of 2024.
The positive Phase 3 trial results and FDA Fast Track designation are likely to boost investor confidence and positively impact TNXP's stock price in the short term. The upcoming NDA submission adds further potential for future gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100